Jeffrey Chamberlain, PhD - Publications

Affiliations: 
University of Washington, Seattle, Seattle, WA 
Area:
muscle gene therapy, DMD

134 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Ramos JN, Hollinger K, Bengtsson NE, Allen JM, Hauschka SD, Chamberlain JS. Development of Novel Micro-dystrophins with Enhanced Functionality. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 30718090 DOI: 10.1016/j.ymthe.2019.01.002  0.6
2018 Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Human Molecular Genetics. PMID 29901725 DOI: 10.1093/hmg/ddy209  0.68
2018 Adams ME, Odom GL, Kim MJ, Chamberlain JS, Froehner SC. Syntrophin binds directly to multiple spectrin-like repeats in dystrophin and mediates binding of nNOS to repeats 16-17. Human Molecular Genetics. PMID 29790927 DOI: 10.1093/hmg/ddy197  0.4
2018 Nelson DM, Lindsay A, Judge LM, Duan D, Chamberlain JS, Lowe DA, Ervasti JM. Variable rescue of microtubule and physiological phenotypes in mdx muscle expressing different miniaturized dystrophins. Human Molecular Genetics. PMID 29618008 DOI: 10.1093/hmg/ddy113  0.68
2018 Halbert CL, Allen JM, Chamberlain JS. AAV6 Vector Production and Purification for Muscle Gene Therapy. Methods in Molecular Biology (Clifton, N.J.). 1687: 257-266. PMID 29067669 DOI: 10.1007/978-1-4939-7374-3_18  0.4
2017 Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Corrigendum: Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nature Communications. 8: 16007. PMID 28643790 DOI: 10.1038/ncomms16007  0.6
2017 Bengtsson NE, Hall JK, Odom GL, Phelps MP, Andrus CR, Hawkins RD, Hauschka SD, Chamberlain JR, Chamberlain JS. Muscle-specific CRISPR/Cas9 dystrophin gene editing ameliorates pathophysiology in a mouse model for Duchenne muscular dystrophy. Nature Communications. 8: 14454. PMID 28195574 DOI: 10.1038/ncomms14454  0.6
2016 Thomson KS, Odom GL, Murry CE, Mahairas GG, Moussavi-Harami F, Teichman SL, Chen X, Hauschka SD, Chamberlain JS, Regnier M. Translation of Cardiac Myosin Activation with 2-deoxy-ATP to Treat Heart Failure via an Experimental Ribonucleotide Reductase-Based Gene Therapy. Jacc. Basic to Translational Science. 1: 666-679. PMID 28553667 DOI: 10.1016/j.jacbts.2016.07.006  0.6
2016 Pisconti A, Banks GB, Babaeijandaghi F, Betta ND, Rossi FM, Chamberlain JS, Olwin BB. Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration. Skeletal Muscle. 6: 34. PMID 27906106 DOI: 10.1186/s13395-016-0104-8  0.56
2016 Pisconti A, Banks GB, Babaeijandaghi F, Betta ND, Rossi FM, Chamberlain JS, Olwin BB. Loss of niche-satellite cell interactions in syndecan-3 null mice alters muscle progenitor cell homeostasis improving muscle regeneration. Skeletal Muscle. 6: 34. PMID 27757223 DOI: 10.1186/s13395-016-0104-8  0.56
2016 Muir LA, Murry CE, Chamberlain J. Pro-survival factors improve functional engraftment of myogenically converted dermal cells into dystrophic skeletal muscle. Stem Cells and Development. PMID 27503462 DOI: 10.1089/scd.2016.0136  0.84
2016 Davey JR, Watt KI, Parker BL, Chaudhuri R, Ryall JG, Cunningham L, Qian H, Sartorelli V, Sandri M, Chamberlain J, James DE, Gregorevic P. Integrated expression analysis of muscle hypertrophy identifies Asb2 as a negative regulator of muscle mass. Jci Insight. 1. PMID 27182554 DOI: 10.1172/jci.insight.85477  0.56
2015 Ramos J, Chamberlain JS. Gene Therapy for Duchenne muscular dystrophy. Expert Opinion On Orphan Drugs. 3: 1255-1266. PMID 26594599 DOI: 10.1517/21678707.2015.1088780  0.88
2015 Bengtsson NE, Seto JT, Hall JK, Chamberlain JS, Odom GL. Progress and prospects of gene therapy clinical trials for the muscular dystrophies. Human Molecular Genetics. PMID 26450518 DOI: 10.1093/hmg/ddv420  0.52
2015 Hollinger K, Chamberlain JS. Viral vector-mediated gene therapies. Current Opinion in Neurology. 28: 522-7. PMID 26263476 DOI: 10.1097/WCO.0000000000000241  0.88
2015 Bisset DR, Stepniak-Konieczna EA, Zavaljevski M, Wei J, Carter GT, Weiss MD, Chamberlain JR. Therapeutic impact of systemic AAV-mediated RNA interference in a mouse model of myotonic dystrophy. Human Molecular Genetics. PMID 26082468 DOI: 10.1093/hmg/ddv219  0.52
2015 Park J, Wicki J, Knoblaugh SE, Chamberlain JS, Lee D. Multi-parametric MRI at 14T for muscular dystrophy mice treated with AAV vector-mediated gene therapy. Plos One. 10: e0124914. PMID 25856443 DOI: 10.1371/journal.pone.0124914  0.88
2015 Su W, Kang J, Sopher B, Gillespie J, Aloi MS, Odom GL, Hopkins S, Case A, Wang DB, Chamberlain JS, Garden GA. Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia. Journal of Neurochemistry. PMID 25708596 DOI: 10.1111/jnc.13081  0.88
2015 Cheever TR, Berkley D, Braun S, Brown RH, Byrne BJ, Chamberlain JS, Cwik V, Duan D, Federoff HJ, High KA, Kaspar BK, Klinger KW, Larkindale J, Lincecum J, Mavilio F, et al. Perspectives on best practices for gene therapy programs. Human Gene Therapy. 26: 127-33. PMID 25654329 DOI: 10.1089/hum.2014.147  0.88
2014 Arnett AL, Konieczny P, Ramos JN, Hall J, Odom G, Yablonka-Reuveni Z, Chamberlain JR, Chamberlain JS. Adeno-associated viral (AAV) vectors do not efficiently target muscle satellite cells. Molecular Therapy. Methods & Clinical Development. 1. PMID 25580445 DOI: 10.1038/mtm.2014.38  0.52
2014 Muir LA, Nguyen QG, Hauschka SD, Chamberlain JS. Engraftment potential of dermal fibroblasts following in vivo myogenic conversion in immunocompetent dystrophic skeletal muscle. Molecular Therapy. Methods & Clinical Development. 1: 14025. PMID 25558461 DOI: 10.1038/mtm.2014.25  0.84
2014 Wei J, Chamberlain JR. Systemic RNAi delivery to the muscles of ROSA26 mice reduces lacZ expression. Plos One. 9: e102053. PMID 25127128 DOI: 10.1371/journal.pone.0102053  0.52
2014 Swiderski K, Shaffer SA, Gallis B, Odom GL, Arnett AL, Scott Edgar J, Baum DM, Chee A, Naim T, Gregorevic P, Murphy KT, Moody J, Goodlett DR, Lynch GS, Chamberlain JS. Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting. Human Molecular Genetics. 23: 6697-711. PMID 25082828 DOI: 10.1093/hmg/ddu388  0.56
2014 Banks GB, Combs AC, Odom GL, Bloch RJ, Chamberlain JS. Muscle structure influences utrophin expression in mdx mice. Plos Genetics. 10: e1004431. PMID 24922526 DOI: 10.1371/journal.pgen.1004431  0.88
2014 Faber RM, Hall JK, Chamberlain JS, Banks GB. Myofiber branching rather than myofiber hyperplasia contributes to muscle hypertrophy in mdx mice. Skeletal Muscle. 4: 10. PMID 24910770 DOI: 10.1186/2044-5040-4-10  0.88
2014 Pearson T, Kabayo T, Ng R, Chamberlain J, McArdle A, Jackson MJ. Skeletal muscle contractions induce acute changes in cytosolic superoxide, but slower responses in mitochondrial superoxide and cellular hydrogen peroxide. Plos One. 9: e96378. PMID 24875639 DOI: 10.1371/journal.pone.0096378  0.88
2014 Taghli-Lamallem O, Jagla K, Chamberlain JS, Bodmer R. Mechanical and non-mechanical functions of Dystrophin can prevent cardiac abnormalities in Drosophila. Experimental Gerontology. 49: 26-34. PMID 24231130 DOI: 10.1016/j.exger.2013.10.015  0.88
2013 Chamberlain JS. Removing the immune response from muscular dystrophy research. Molecular Therapy : the Journal of the American Society of Gene Therapy. 21: 1821-2. PMID 24081124 DOI: 10.1038/mt.2013.209  0.88
2013 Ieronimakis N, Pantoja M, Hays AL, Dosey TL, Qi J, Fischer KA, Hoofnagle AN, Sadilek M, Chamberlain JS, Ruohola-Baker H, Reyes M. Increased sphingosine-1-phosphate improves muscle regeneration in acutely injured mdx mice. Skeletal Muscle. 3: 20. PMID 23915702 DOI: 10.1186/2044-5040-3-20  0.88
2013 Konieczny P, Swiderski K, Chamberlain JS. Gene and cell-mediated therapies for muscular dystrophy. Muscle & Nerve. 47: 649-63. PMID 23553671 DOI: 10.1002/mus.23738  0.88
2013 Bieber S, Halldorson JB, Finn E, Ahmad S, Chamberlain JS, Odom GL. Extracorporeal delivery of rAAV with metabolic exchange and oxygenation. Scientific Reports. 3: 1538. PMID 23528884 DOI: 10.1038/srep01538  0.88
2013 Filareto A, Parker S, Darabi R, Borges L, Iacovino M, Schaaf T, Mayerhofer T, Chamberlain JS, Ervasti JM, McIvor RS, Kyba M, Perlingeiro RC. An ex vivo gene therapy approach to treat muscular dystrophy using inducible pluripotent stem cells. Nature Communications. 4: 1549. PMID 23462992 DOI: 10.1038/ncomms2550  0.88
2013 Arnett AL, Beutler LR, Quintana A, Allen J, Finn E, Palmiter RD, Chamberlain JS. Heparin-binding correlates with increased efficiency of AAV1- and AAV6-mediated transduction of striated muscle, but negatively impacts CNS transduction. Gene Therapy. 20: 497-503. PMID 22855092 DOI: 10.1038/gt.2012.60  0.88
2012 Chamberlain JS. Genetics. A genetic intervention stands a skip away from clinical tests. Science (New York, N.Y.). 338: 1431-2. PMID 23239725 DOI: 10.1126/science.1233074  0.88
2012 Winbanks CE, Weeks KL, Thomson RE, Sepulveda PV, Beyer C, Qian H, Chen JL, Allen JM, Lancaster GI, Febbraio MA, Harrison CA, McMullen JR, Chamberlain JS, Gregorevic P. Follistatin-mediated skeletal muscle hypertrophy is regulated by Smad3 and mTOR independently of myostatin. The Journal of Cell Biology. 197: 997-1008. PMID 22711699 DOI: 10.1083/jcb.201109091  0.88
2012 Wang Z, Storb R, Halbert CL, Banks GB, Butts TM, Finn EE, Allen JM, Miller AD, Chamberlain JS, Tapscott SJ. Successful regional delivery and long-term expression of a dystrophin gene in canine muscular dystrophy: a preclinical model for human therapies. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1501-7. PMID 22692496 DOI: 10.1038/mt.2012.111  0.88
2012 Seto JT, Ramos JN, Muir L, Chamberlain JS, Odom GL. Gene replacement therapies for duchenne muscular dystrophy using adeno-associated viral vectors. Current Gene Therapy. 12: 139-51. PMID 22533379 DOI: 10.2174/156652312800840603  0.88
2012 Ng R, Banks GB, Hall JK, Muir LA, Ramos JN, Wicki J, Odom GL, Konieczny P, Seto J, Chamberlain JR, Chamberlain JS. Animal models of muscular dystrophy. Progress in Molecular Biology and Translational Science. 105: 83-111. PMID 22137430 DOI: 10.1016/B978-0-12-394596-9.00004-4  0.88
2012 Arnett ALH, Ramos JN, Chamberlain JS. Gene therapy of skeletal muscle disorders using viral vectors Muscle. 2: 1045-1051. DOI: 10.1016/B978-0-12-381510-1.00076-4  0.88
2011 Arnett AL, Garikipati D, Wang Z, Tapscott S, Chamberlain JS. Immune Responses to rAAV6: The Influence of Canine Parvovirus Vaccination and Neonatal Administration of Viral Vector. Frontiers in Microbiology. 2: 220. PMID 22065964 DOI: 10.3389/fmicb.2011.00220  0.88
2011 Wang Z, Tapscott SJ, Chamberlain JS, Storb R. Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials. Frontiers in Microbiology. 2: 201. PMID 21980317 DOI: 10.3389/fmicb.2011.00201  0.88
2011 Judge LM, Arnett AL, Banks GB, Chamberlain JS. Expression of the dystrophin isoform Dp116 preserves functional muscle mass and extends lifespan without preventing dystrophy in severely dystrophic mice. Human Molecular Genetics. 20: 4978-90. PMID 21949353 DOI: 10.1093/hmg/ddr433  0.88
2011 Townsend D, Daly M, Chamberlain JS, Metzger JM. Age-dependent dystrophin loss and genetic reconstitution establish a molecular link between dystrophin and heart performance during aging. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1821-5. PMID 21730971 DOI: 10.1038/mt.2011.120  0.88
2011 Suga T, Kimura E, Morioka Y, Ikawa M, Li S, Uchino K, Uchida Y, Yamashita S, Maeda Y, Chamberlain JS, Uchino M. Muscle fiber type-predominant promoter activity in lentiviral-mediated transgenic mouse. Plos One. 6: e16908. PMID 21445245 DOI: 10.1371/journal.pone.0016908  0.88
2011 Goyenvalle A, Seto JT, Davies KE, Chamberlain J. Therapeutic approaches to muscular dystrophy. Human Molecular Genetics. 20: R69-78. PMID 21436158 DOI: 10.1093/hmg/ddr105  0.88
2011 Odom GL, Gregorevic P, Allen JM, Chamberlain JS. Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 36-45. PMID 20859263 DOI: 10.1038/mt.2010.205  0.88
2010 Chamberlain JS. Duchenne muscular dystrophy models show their age. Cell. 143: 1040-2. PMID 21183068 DOI: 10.1016/j.cell.2010.12.005  0.88
2010 Hall JK, Banks GB, Chamberlain JS, Olwin BB. Prevention of muscle aging by myofiber-associated satellite cell transplantation. Science Translational Medicine. 2: 57ra83. PMID 21068442 DOI: 10.1126/scitranslmed.3001081  0.88
2010 Babcock MA, Kostova FV, Moxley RT, Chamberlain JS, Maria BL. Muscular dystrophy: new opportunities for diagnosis and treatment. Journal of Child Neurology. 25: 1080-97. PMID 20558673 DOI: 10.1177/0883073810371000  0.88
2010 Banks GB, Combs AC, Chamberlain JS. Sequencing protocols to genotype mdx, mdx(4cv), and mdx(5cv) mice. Muscle & Nerve. 42: 268-70. PMID 20544945 DOI: 10.1002/mus.21700  0.88
2010 Carter GT, Han JJ, Chamberlain JR, Chamberlain JS. On fixing broken muscle...fall seven times, stand up eight--Japanese proverb. Muscle & Nerve. 41: 737-9. PMID 20513100 DOI: 10.1002/mus.21704  0.88
2010 Banks GB, Judge LM, Allen JM, Chamberlain JS. The polyproline site in hinge 2 influences the functional capacity of truncated dystrophins. Plos Genetics. 6: e1000958. PMID 20502633 DOI: 10.1371/journal.pgen.1000958  0.88
2010 Odom GL, Banks GB, Schultz BR, Gregorevic P, Chamberlain JS. Preclinical studies for gene therapy of Duchenne muscular dystrophy. Journal of Child Neurology. 25: 1149-57. PMID 20498332 DOI: 10.1177/0883073810371006  0.88
2010 Li D, Bareja A, Judge L, Yue Y, Lai Y, Fairclough R, Davies KE, Chamberlain JS, Duan D. Sarcolemmal nNOS anchoring reveals a qualitative difference between dystrophin and utrophin. Journal of Cell Science. 123: 2008-13. PMID 20483958 DOI: 10.1242/jcs.064808  0.88
2010 Friedrich O, Both M, Weber C, Schürmann S, Teichmann MD, von Wegner F, Fink RH, Vogel M, Chamberlain JS, Garbe C. Microarchitecture is severely compromised but motor protein function is preserved in dystrophic mdx skeletal muscle. Biophysical Journal. 98: 606-16. PMID 20159157 DOI: 10.1016/j.bpj.2009.11.005  0.88
2010 Chamberlain JR, Chamberlain JS. Muscling in: Gene therapies for muscular dystrophy target RNA. Nature Medicine. 16: 170-1. PMID 20134472 DOI: 10.1038/nm0210-170  0.88
2010 Wang Z, Storb R, Lee D, Kushmerick MJ, Chu B, Berger C, Arnett A, Allen J, Chamberlain JS, Riddell SR, Tapscott SJ. Immune responses to AAV in canine muscle monitored by cellular assays and noninvasive imaging. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 617-24. PMID 20040912 DOI: 10.1038/mt.2009.294  0.88
2010 Kimura E, Li S, Gregorevic P, Fall BM, Chamberlain JS. Dystrophin delivery to muscles of mdx mice using lentiviral vectors leads to myogenic progenitor targeting and stable gene expression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 18: 206-13. PMID 19888194 DOI: 10.1038/mt.2009.253  0.88
2010 Garikipati D, Chamberlain JS. Systemic gene delivery for muscle gene therapy Muscle Gene Therapy. 163-179. DOI: 10.1007/978-1-4419-1207-7_10  0.88
2009 Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Chamberlain JS. Erratum to "Efficient Transduction of Skeletal Muscle Using Vectors Based on Adeno-associated Virus Serotype 6". Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1482. PMID 28160909 DOI: 10.1038/mt.2009.135  0.56
2009 Townsend D, Yasuda S, Chamberlain J, Metzger JM. Cardiac consequences to skeletal muscle-centric therapeutics for Duchenne muscular dystrophy. Trends in Cardiovascular Medicine. 19: 50-55. PMID 19577712 DOI: 10.1016/j.tcm.2009.04.006  0.88
2009 Muir LA, Chamberlain JS. Emerging strategies for cell and gene therapy of the muscular dystrophies. Expert Reviews in Molecular Medicine. 11: e18. PMID 19555515 DOI: 10.1017/S1462399409001100  0.88
2009 Gregorevic P, Schultz BR, Allen JM, Halldorson JB, Blankinship MJ, Meznarich NA, Kuhr CS, Doremus C, Finn E, Liggitt D, Chamberlain JS. Evaluation of vascular delivery methodologies to enhance rAAV6-mediated gene transfer to canine striated musculature. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 1427-33. PMID 19471246 DOI: 10.1038/mt.2009.116  0.88
2009 Arnett AL, Chamberlain JR, Chamberlain JS. Therapy for neuromuscular disorders. Current Opinion in Genetics & Development. 19: 290-7. PMID 19411172 DOI: 10.1016/j.gde.2009.03.005  0.88
2009 Wang Z, Chamberlain JS, Tapscott SJ, Storb R. Gene therapy in large animal models of muscular dystrophy. Ilar Journal / National Research Council, Institute of Laboratory Animal Resources. 50: 187-98. PMID 19293461  0.88
2009 Lai Y, Thomas GD, Yue Y, Yang HT, Li D, Long C, Judge L, Bostick B, Chamberlain JS, Terjung RL, Duan D. Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. The Journal of Clinical Investigation. 119: 624-35. PMID 19229108 DOI: 10.1172/JCI36612  0.88
2009 Masson R, Nicklin SA, Craig MA, McBride M, Gilday K, Gregorevic P, Allen JM, Chamberlain JS, Smith G, Graham D, Dominiczak AF, Napoli C, Baker AH. Onset of experimental severe cardiac fibrosis is mediated by overexpression of Angiotensin-converting enzyme 2. Hypertension. 53: 694-700. PMID 19221212 DOI: 10.1161/HYPERTENSIONAHA.108.122333  0.88
2009 Banks GB, Chamberlain JS, Froehner SC. Truncated dystrophins can influence neuromuscular synapse structure. Molecular and Cellular Neurosciences. 40: 433-41. PMID 19171194 DOI: 10.1016/j.mcn.2008.12.011  0.88
2008 Banks GB, Chamberlain JS. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies. Current Topics in Developmental Biology. 84: 431-53. PMID 19186250 DOI: 10.1016/S0070-2153(08)00609-1  0.88
2008 Teichmann MD, Wegner FV, Fink RH, Chamberlain JS, Launikonis BS, Martinac B, Friedrich O. Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression. Plos One. 3: e3644. PMID 18982068 DOI: 10.1371/journal.pone.0003644  0.88
2008 Kobayashi YM, Rader EP, Crawford RW, Iyengar NK, Thedens DR, Faulkner JA, Parikh SV, Weiss RM, Chamberlain JS, Moore SA, Campbell KP. Sarcolemma-localized nNOS is required to maintain activity after mild exercise. Nature. 456: 511-5. PMID 18953332 DOI: 10.1038/nature07414  0.88
2008 Percival JM, Anderson KN, Gregorevic P, Chamberlain JS, Froehner SC. Functional deficits in nNOSmu-deficient skeletal muscle: myopathy in nNOS knockout mice. Plos One. 3: e3387. PMID 18852886 DOI: 10.1371/journal.pone.0003387  0.88
2008 Banks GB, Combs AC, Chamberlain JR, Chamberlain JS. Molecular and cellular adaptations to chronic myotendinous strain injury in mdx mice expressing a truncated dystrophin. Human Molecular Genetics. 17: 3975-86. PMID 18799475 DOI: 10.1093/hmg/ddn301  0.88
2008 Odom GL, Gregorevic P, Allen JM, Finn E, Chamberlain JS. Microutrophin delivery through rAAV6 increases lifespan and improves muscle function in dystrophic dystrophin/utrophin-deficient mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1539-45. PMID 18665159 DOI: 10.1038/mt.2008.149  0.88
2008 Friedrich O, von Wegner F, Chamberlain JS, Fink RH, Rohrbach P. L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. Plos One. 3: e1762. PMID 18516256 DOI: 10.1371/journal.pone.0001762  0.88
2008 Kimura E, Han JJ, Li S, Fall B, Ra J, Haraguchi M, Tapscott SJ, Chamberlain JS. Cell-lineage regulated myogenesis for dystrophin replacement: a novel therapeutic approach for treatment of muscular dystrophy. Human Molecular Genetics. 17: 2507-17. PMID 18511457 DOI: 10.1093/hmg/ddn151  0.88
2008 Schultz BR, Chamberlain JS. Recombinant adeno-associated virus transduction and integration. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1189-99. PMID 18500252 DOI: 10.1038/mt.2008.103  0.88
2008 Stone D, Liu Y, Li ZY, Strauss R, Finn EE, Allen JM, Chamberlain JS, Lieber A. Biodistribution and safety profile of recombinant adeno-associated virus serotype 6 vectors following intravenous delivery. Journal of Virology. 82: 7711-5. PMID 18480442 DOI: 10.1128/JVI.00542-08  0.88
2008 Friedrich O, Weber C, Wegner FV, Chamberlain JS, Fink RHA. Unloaded speed of shortening in voltage-clamped intact skeletal muscle fibers from wt, mdx, and transgenic minidystrophin mice using a novel high-speed acquisition system Biophysical Journal. 94: 4751-4765. PMID 18424498 DOI: 10.1529/biophysj.107.126557  0.88
2008 Townsend D, Yasuda S, Li S, Chamberlain JS, Metzger JM. Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 832-5. PMID 18414480 DOI: 10.1038/mt.2008.52  0.88
2008 Gregorevic P, Blankinship MJ, Allen JM, Chamberlain JS. Systemic microdystrophin gene delivery improves skeletal muscle structure and function in old dystrophic mdx mice. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 657-64. PMID 18334986 DOI: 10.1038/mt.2008.28  0.88
2008 Taghli-Lamallem O, Akasaka T, Hogg G, Nudel U, Yaffe D, Chamberlain JS, Ocorr K, Bodmer R. Dystrophin deficiency in Drosophila reduces lifespan and causes a dilated cardiomyopathy phenotype. Aging Cell. 7: 237-49. PMID 18221418 DOI: 10.1111/j.1474-9726.2008.00367.x  0.88
2008 Faulkner JA, Ng R, Davis CS, Li S, Chamberlain JS. Diaphragm muscle strip preparation for evaluation of gene therapies in mdx mice. Clinical and Experimental Pharmacology & Physiology. 35: 725-9. PMID 18215182 DOI: 10.1111/j.1440-1681.2007.04865.x  0.88
2008 Gregorevic P, Meznarich NA, Blankinship MJ, Crawford RW, Chamberlain JS. Fluorophore-labeled myosin-specific antibodies simplify muscle-fiber phenotyping. Muscle & Nerve. 37: 104-6. PMID 17691104 DOI: 10.1002/mus.20877  0.88
2008 Taghli-Lamallem O, Bodmer R, Chamberlain JS, Cammarato A. Genetics and pathogenic mechanisms of cardiomyopathies in the Drosophila model Drug Discovery Today: Disease Models. 5: 125-134. DOI: 10.1016/j.ddmod.2009.02.005  0.88
2007 Percival JM, Gregorevic P, Odom GL, Banks GB, Chamberlain JS, Froehner SC. rAAV6-microdystrophin rescues aberrant Golgi complex organization in mdx skeletal muscles. Traffic (Copenhagen, Denmark). 8: 1424-39. PMID 17714427 DOI: 10.1111/j.1600-0854.2007.00622.x  0.88
2007 Xiong F, Xiao S, Yu M, Li W, Zheng H, Shang Y, Peng F, Zhao C, Zhou W, Chen H, Fang L, Chamberlain JS, Zhang C. Enhanced effect of microdystrophin gene transfection by HSV-VP22 mediated intercellular protein transport. Bmc Neuroscience. 8: 50. PMID 17617925 DOI: 10.1186/1471-2202-8-50  0.96
2007 Banks GB, Gregorevic P, Allen JM, Finn EE, Chamberlain JS. Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain. Human Molecular Genetics. 16: 2105-13. PMID 17588958 DOI: 10.1093/hmg/ddm158  0.88
2007 Xiong F, Xiao S, Peng F, Zheng H, Yu M, Ruan Y, Li W, Shang Y, Zhao C, Zhou W, Chen H, Chamberlain JS, Fang L, Zhang C. Herpes simplex virus VP22 enhances adenovirus-mediated microdystrophin gene transfer to skeletal muscles in dystrophin-deficient (mdx) mice. Human Gene Therapy. 18: 490-501. PMID 17550336 DOI: 10.1089/hum.2006.155  0.96
2007 Townsend D, Blankinship MJ, Allen JM, Gregorevic P, Chamberlain JS, Metzger JM. Systemic administration of micro-dystrophin restores cardiac geometry and prevents dobutamine-induced cardiac pump failure. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1086-92. PMID 17440445 DOI: 10.1038/sj.mt.6300144  0.88
2007 Wang Z, Kuhr CS, Allen JM, Blankinship M, Gregorevic P, Chamberlain JS, Tapscott SJ, Storb R. Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 1160-6. PMID 17426713 DOI: 10.1038/sj.mt.6300161  0.88
2007 Chamberlain JS, Metzger J, Reyes M, Townsend D, Faulkner JA. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 21: 2195-204. PMID 17360850 DOI: 10.1096/fj.06-7353com  0.88
2007 Dellavalle A, Sampaolesi M, Tonlorenzi R, Tagliafico E, Sacchetti B, Perani L, Innocenzi A, Galvez BG, Messina G, Morosetti R, Li S, Belicchi M, Peretti G, Chamberlain JS, Wright WE, et al. Pericytes of human skeletal muscle are myogenic precursors distinct from satellite cells. Nature Cell Biology. 9: 255-67. PMID 17293855 DOI: 10.1038/ncb1542  0.88
2007 Chamberlain JS. ACE inhibitor bulks up muscle. Nature Medicine. 13: 125-6. PMID 17290265 DOI: 10.1038/nm0207-125  0.88
2007 Salva MZ, Himeda CL, Tai PW, Nishiuchi E, Gregorevic P, Allen JM, Finn EE, Nguyen QG, Blankinship MJ, Meuse L, Chamberlain JS, Hauschka SD. Design of tissue-specific regulatory cassettes for high-level rAAV-mediated expression in skeletal and cardiac muscle. Molecular Therapy : the Journal of the American Society of Gene Therapy. 15: 320-9. PMID 17235310 DOI: 10.1038/sj.mt.6300027  0.88
2007 Wang Z, Allen JM, Riddell SR, Gregorevic P, Storb R, Tapscott SJ, Chamberlain JS, Kuhr CS. Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy. Human Gene Therapy. 18: 18-26. PMID 17176210 DOI: 10.1089/hum.2006.093  0.88
2007 Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochimica Et Biophysica Acta. 1772: 243-62. PMID 17064882 DOI: 10.1016/j.bbadis.2006.09.007  0.88
2007 Gregorevic P, Chamberlain JS. Therapeutic Gene Transfer to Skeletal Muscle Concepts in Genetic Medicine. 123-128. DOI: 10.1002/9780470184585.ch9  0.88
2006 Chamberlain JS. Stem-cell biology: a move in the right direction. Nature. 444: 552-3. PMID 17108968 DOI: 10.1038/nature05406  0.88
2006 Gregorevic P, Allen JM, Minami E, Blankinship MJ, Haraguchi M, Meuse L, Finn E, Adams ME, Froehner SC, Murry CE, Chamberlain JS. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nature Medicine. 12: 787-9. PMID 16819550 DOI: 10.1038/nm1439  0.88
2006 Bachrach E, Perez AL, Choi YH, Illigens BM, Jun SJ, del Nido P, McGowan FX, Li S, Flint A, Chamberlain J, Kunkel LM. Muscle engraftment of myogenic progenitor cells following intraarterial transplantation. Muscle & Nerve. 34: 44-52. PMID 16634061 DOI: 10.1002/mus.20560  0.88
2006 Li S, Kimura E, Ng R, Fall BM, Meuse L, Reyes M, Faulkner JA, Chamberlain JS. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy. Human Molecular Genetics. 15: 1610-22. PMID 16595609 DOI: 10.1093/hmg/ddl082  0.88
2006 Judge LM, Haraguchiln M, Chamberlain JS. Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex. Journal of Cell Science. 119: 1537-46. PMID 16569668 DOI: 10.1242/jcs.02857  0.88
2006 Blankinship MJ, Gregorevic P, Chamberlain JS. Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors. Molecular Therapy : the Journal of the American Society of Gene Therapy. 13: 241-9. PMID 16361117 DOI: 10.1016/j.ymthe.2005.11.001  0.88
2006 Han JJ, Carter GT, Ra JJ, Abresch RT, Chamberlain JS, Robinson LR. Electromyographic studies in mdx and wild-type C57 mice. Muscle & Nerve. 33: 208-14. PMID 16281275 DOI: 10.1002/mus.20455  0.88
2005 Judge LM, Chamberlain JS. Gene therapy for Duchenne muscular dystrophy: AAV leads the way. Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology / Edited by the Gaetano Conte Academy For the Study of Striated Muscle Diseases. 24: 184-93. PMID 16629052  0.88
2005 Banks GB, Chamberlain JS. Relevance of motoneuron specification and programmed cell death in embryos to therapy of ALS. Birth Defects Research. Part C, Embryo Today : Reviews. 75: 294-304. PMID 16425251 DOI: 10.1002/bdrc.20051  0.88
2005 Lai Y, Yue Y, Liu M, Ghosh A, Engelhardt JF, Chamberlain JS, Duan D. Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nature Biotechnology. 23: 1435-9. PMID 16244658 DOI: 10.1038/nbt1153  0.88
2005 Gregorevic P, Chamberlain JS. Functional enhancement of skeletal muscle by gene transfer. Physical Medicine and Rehabilitation Clinics of North America. 16: 875-87, vii-viii. PMID 16214049 DOI: 10.1016/j.pmr.2005.08.011  0.88
2005 Reyes M, Li S, Foraker J, Kimura E, Chamberlain JS. Donor origin of multipotent adult progenitor cells in radiation chimeras. Blood. 106: 3646-9. PMID 16099880 DOI: 10.1182/blood-2004-12-4603  0.88
2005 Abmayr S, Gregorevic P, Allen JM, Chamberlain JS. Phenotypic improvement of dystrophic muscles by rAAV/microdystrophin vectors is augmented by Igf1 codelivery. Molecular Therapy : the Journal of the American Society of Gene Therapy. 12: 441-50. PMID 16099410 DOI: 10.1016/j.ymthe.2005.04.001  0.88
2005 Weisbart RH, Hansen JE, Nishimura RN, Chan G, Wakelin R, Chang SS, Baresi L, Chamberlain JS. An intracellular delivery vehicle for protein transduction of micro-dystrophin. Journal of Drug Targeting. 13: 81-7. PMID 15823959 DOI: 10.1080/10611860400029002  0.88
2005 Li S, Kimura E, Fall BM, Reyes M, Angello JC, Welikson R, Hauschka SD, Chamberlain JS. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin. Gene Therapy. 12: 1099-108. PMID 15759015 DOI: 10.1038/sj.gt.3302505  0.88
2005 Liu M, Yue Y, Harper SQ, Grange RW, Chamberlain JS, Duan D. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 245-56. PMID 15668136 DOI: 10.1016/j.ymthe.2004.09.013  0.88
2005 Balcaitis S, Weinstein JR, Li S, Chamberlain JS, Möller T. Lentiviral transduction of microglial cells. Glia. 50: 48-55. PMID 15625717 DOI: 10.1002/glia.20146  0.88
2004 Gregorevic P, Blankinship MJ, Chamberlain JS. Viral vectors for gene transfer to striated muscle. Current Opinion in Molecular Therapeutics. 6: 491-8. PMID 15537050  0.88
2004 Blankinship MJ, Gregorevic P, Allen JM, Harper SQ, Harper H, Halbert CL, Miller AD, Miller DA, Chamberlain JS. Efficient transduction of skeletal muscle using vectors based on adeno-associated virus serotype 6. Molecular Therapy : the Journal of the American Society of Gene Therapy. 10: 671-8. PMID 15451451 DOI: 10.1016/j.ymthe.2004.07.016  0.88
2004 Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Differential expression of the skeletal muscle proteome in mdx mice at different ages. Electrophoresis. 25: 2576-85. PMID 15300778 DOI: 10.1002/elps.200406013  0.88
2004 Gregorevic P, Blankinship MJ, Allen JM, Crawford RW, Meuse L, Miller DG, Russell DW, Chamberlain JS. Systemic delivery of genes to striated muscles using adeno-associated viral vectors. Nature Medicine. 10: 828-34. PMID 15273747 DOI: 10.1038/nm1085  0.88
2004 Bachrach E, Li S, Perez AL, Schienda J, Liadaki K, Volinski J, Flint A, Chamberlain J, Kunkel LM. Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 101: 3581-6. PMID 14993597 DOI: 10.1073/pnas.0400373101  0.88
2003 Ge Y, Molloy MP, Chamberlain JS, Andrews PC. Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. Proteomics. 3: 1895-903. PMID 14625851 DOI: 10.1002/pmic.200300561  0.88
2003 Yue Y, Li Z, Harper SQ, Davisson RL, Chamberlain JS, Duan D. Microdystrophin gene therapy of cardiomyopathy restores dystrophin-glycoprotein complex and improves sarcolemma integrity in the mdx mouse heart. Circulation. 108: 1626-32. PMID 12952841 DOI: 10.1161/01.CIR.0000089371.11664.27  0.88
2003 Gregorevic P, Chamberlain JS. Gene therapy for muscular dystrophy - a review of promising progress. Expert Opinion On Biological Therapy. 3: 803-14. PMID 12880380 DOI: 10.1517/14712598.3.5.803  0.56
2003 Scott JM, Chamberlain JS. Gutted adenoviral vectors for gene transfer to muscle. Methods in Molecular Biology (Clifton, N.J.). 219: 19-28. PMID 12596996  0.88
2002 Chamberlain JS. Gene therapy of muscular dystrophy. Human Molecular Genetics. 11: 2355-62. PMID 12351570  0.88
2002 DelloRusso C, Scott JM, Hartigan-O'Connor D, Salvatori G, Barjot C, Robinson AS, Crawford RW, Brooks SV, Chamberlain JS. Functional correction of adult mdx mouse muscle using gutted adenoviral vectors expressing full-length dystrophin. Proceedings of the National Academy of Sciences of the United States of America. 99: 12979-84. PMID 12271128 DOI: 10.1073/pnas.202300099  0.88
2002 Gussoni E, Bennett RR, Muskiewicz KR, Meyerrose T, Nolta JA, Gilgoff I, Stein J, Chan YM, Lidov HG, Bönnemann CG, Von Moers A, Morris GE, Den Dunnen JT, Chamberlain JS, Kunkel LM, et al. Long-term persistence of donor nuclei in a Duchenne muscular dystrophy patient receiving bone marrow transplantation. The Journal of Clinical Investigation. 110: 807-14. PMID 12235112 DOI: 10.1172/JCI16098  0.88
2002 Barjot C, Hartigan-O'Connor D, Salvatori G, Scott JM, Chamberlain JS. Gutted adenoviral vector growth using E1/E2b/E3-deleted helper viruses. The Journal of Gene Medicine. 4: 480-9. PMID 12221641 DOI: 10.1002/jgm.305  0.52
2002 Scott JM, Li S, Harper SQ, Welikson R, Bourque D, DelloRusso C, Hauschka SD, Chamberlain JS. Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. Neuromuscular Disorders : Nmd. 12: S23-9. PMID 12206791 DOI: 10.1016/S0960-8966(02)00078-0  0.88
2002 Harper SQ, Crawford RW, DelloRusso C, Chamberlain JS. Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. Human Molecular Genetics. 11: 1807-15. PMID 12140183  0.88
2002 Crosbie RH, Dovico SA, Flanagan JD, Chamberlain JS, Ownby CL, Campbell KP. Characterization of aquaporin-4 in muscle and muscular dystrophy. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 16: 943-9. PMID 12087055 DOI: 10.1096/fj.01-0327com  0.88
2002 Warner LE, DelloRusso C, Crawford RW, Rybakova IN, Patel JR, Ervasti JM, Chamberlain JS. Expression of Dp260 in muscle tethers the actin cytoskeleton to the dystrophin-glycoprotein complex and partially prevents dystrophy. Human Molecular Genetics. 11: 1095-105. PMID 11978768  0.88
2002 Harper SQ, Hauser MA, DelloRusso C, Duan D, Crawford RW, Phelps SF, Harper HA, Robinson AS, Engelhardt JF, Brooks SV, Chamberlain JS. Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nature Medicine. 8: 253-61. PMID 11875496 DOI: 10.1038/nm0302-253  0.88
2001 Dellorusso C, Crawford RW, Chamberlain JS, Brooks SV. Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. Journal of Muscle Research and Cell Motility. 22: 467-75. PMID 11964072 DOI: 10.1023/A:1014587918367  0.88
Show low-probability matches.